Antibody Contract Manufacturing Market Growth

Increased Demand for Biologics to Drive Antibody Contract Manufacturing Market Growth; Revenue to Cross US$ 47 billion by 2035 | Roots Analysis

According to a recently published report by Roots Analysis, with over 100 therapeutic monoclonal antibodies and antibody-based products in the market, the demand for manufacturing of such products is anticipated to increase in the next decade.

Antibody Contract Manufacturing Market Overview

The global antibody contract manufacturing market size is estimated to reach USD 47 billion by 2035, growing at a CAGR of 10.04% during the forecast period 2024-2035.

The antibody contract manufacturing market is witnessing robust growth, driven by several key factors such as rising demand for biologics, prevalence of chronic diseases and shifting trend towards personalized medicine. This dominance is expected to persist, as advanced antibodies such as bispecific antibodies and antibody fragments gain prominence. However, the challenges inherent in development and production of biologics have led to a widespread practice of outsourcing antibody manufacturing operations. As a result, the market for antibody contract manufacturing or monoclonal antibody contract manufacturing is fiercely competitive, featuring companies of various sizes. It is worth mentioning that some players are engaged in providing comprehensive solutions, from antibody development to commercial production however, sponsors are likely to rely on contract service providers owing to substantial costs and time-intensive process of setting up the infrastructure. Consequently, CMOs are expanding their capacities and capabilities in order to consolidate their position in the market and meet the escalating demand.

Browse 100+ figures and 145+ market data tables spread across 360+ pages and detailed Table of Content on “Antibody Contract Manufacturing Market by Type of Antibody Manufactured, Type of Expression System Used, Scale of Operation and Geographical Regions: Industry Trends and Global Forecasts, Till 2035” here:
https://www.rootsanalysis.com/reports/antibody-cmo-market/295.html

Market Drivers

The antibody contract manufacturing market is driven by various factors that are likely to collectively shape the market trajectory and growth. Firstly, increased demand for biologics, fueled by the rising incidence of chronic diseases such as cancer and autoimmune disorders, drives the need for efficient and cost-effective production solutions. Additionally, the advent of biosimilars impelled by the expiration of patents on blockbuster biologics, signifies the demand for antibody contract manufacturing services. Moreover, ongoing advancements in bioprocessing technologies, including single-use bioreactors and downstream purification methods, enhance manufacturing efficiency and scalability, attracting biopharma companies seeking agile manufacturing partners. Simultaneously, the outsourcing trend prevalent in the pharmaceutical industry, driven by the desire to optimize costs and focus on core competencies, further propel the antibody contract manufacturing market growth. The globalization of the biopharmaceutical market and the increasing adoption of technological innovation and automation, further contributes to the expansion and evolution of the antibody contract manufacturing market.

Market Restraints

While the antibody contract manufacturing market is experiencing substantial growth, it is not without challenges. One of the primary restraints is the stringent regulatory guidelines governing antibody production. Compliance to regulatory bodies such as FDA and EMA can substantially increase costs and timelines of drugs approval. Moreover, the inherent complex nature of antibody necessitates specialized facilities and equipment for their manufacturing, leading to substantial upfront investments and high operational costs. Further, capacity constraints compound these challenges, as the demand for antibody manufacturing often exceeds the available capacity of contract manufacturing organizations. This can result in prolonged lead time and delay in production, potentially impacting the antibody development. Lastly, immense competition within the antibody contract manufacturing market exerts pressure on pricing and profit margins, making it challenging for CMOs to maintain profitability while delivering high-quality services. Overcoming such challenges requires continuous innovation, investment in technology and infrastructure, and a proactive approach to manage the risks for navigating the complexities of the antibody contract manufacturing landscape.

Growth Factors

Despite the challenges, several growth factors continue to drive the antibody contract manufacturing market forward including technological advancements with ongoing innovations in bioprocessing technologies such as single-use systems, automation, and data analytics. These innovations enhance manufacturing efficiency, scalability, and product quality, positioning CMOs at the forefront of industry competitiveness. Further, expanding pipelines of biologic drugs, including monoclonal antibodies, biosimilars, and novel formats like bispecific antibodies, further fuel the demand for manufacturing services. Biopharmaceutical companies increasingly rely on CMOs to accelerate the development and commercialization of these therapies, driving market expansion. Moreover, rapidly increasing pharmaceutical activities in emerging markets present opportunities for CMOs to expand their global footprint and forge partnerships with local biopharmaceutical companies. This expansion into emerging markets is driven by several factors such as rising healthcare expenditures, favorable regulatory environments, and growing patient populations.

Antibody Contract Manufacturing Market Segments

Based on the type of antibody manufactured, the market is segmented into monoclonal antibodies and bispecific antibodies

• The monoclonal antibodies segment is likely to capture the largest revenue share of 97% in the antibody contract manufacturing market, in 2024.
• Further, bispecific antibodies segment is anticipated to witness the highest annual growth rate of 12.83% during the forecast period.

Based on the type of expression system used, the market is segmented into mammalian expression and microbial expression

• The mammalian expression system is likely to capture the largest revenue share of close to 85% in antibody contract manufacturing market, in 2024.
• The mammalian expression system is anticipated to witness the highest annual growth rate of around 10.4% during the forecast period.

Based on the scale of operation, the market is segmented into commercial and clinical scale

• Antibody contract manufacturing at commercial scale is likely to capture the largest revenue share of 96% in 2024.
• The antibody contract manufacturing market at commercial scale is anticipated to witness a market growth rate of 10.2% annually during the forecast period.

Based on the Geographical Regions, the market is segmented into North America, Europe, Asia, Latin America and Middle East and North Africa

• North America dominated the antibody contract manufacturing market and accounted for the largest revenue share of 54% in 2024.
• In Asia, the antibody contract manufacturing market is anticipated to grow at a higher growth rate of 11.23% during the forecast period.

Key Companies Profiled

The antibody contract manufacturing market report also includes detailed profiles of key players (listed below) that offer services for antibody contract manufacturing:

• AGC Biologics
• Aldevron
• Emergent BioSolutions
• Eurofins CDMO
• FUJIFILM Diosynth Biotechnologies
• KBI Biopharma
• Lonza
• Nitto Avecia Pharma Services
• Novasep
• Pierre Fabre
• Samsung BioLogics
• Synthon
• Thermo Fisher Scientific

You Can Download Free Sample PDF Copy of This Report At:
https://www.rootsanalysis.com/reports/antibody-cmo-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in market research, competitive intelligence and consulting services. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com